Shares of Seattle Genetics, Inc. (NASDAQ:SGEN) have been assigned a consensus recommendation of “Hold” from the twenty-six brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, thirteen have issued a hold recommendation, ten have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $63.76.
Several analysts recently weighed in on the stock. Oppenheimer reiterated a “hold” rating on shares of Seattle Genetics in a report on Tuesday. Cantor Fitzgerald set a $46.00 price target on shares of Seattle Genetics and gave the company a “hold” rating in a report on Monday, October 2nd. BidaskClub upgraded shares of Seattle Genetics from a “sell” rating to a “hold” rating in a report on Saturday, December 30th. Barclays lifted their price target on shares of Seattle Genetics from $55.00 to $60.00 and gave the company an “equal weight” rating in a report on Monday, October 16th. Finally, Cowen reiterated a “hold” rating on shares of Seattle Genetics in a report on Sunday, October 29th.
Seattle Genetics (NASDAQ SGEN) opened at $55.53 on Friday. Seattle Genetics has a fifty-two week low of $45.31 and a fifty-two week high of $71.32. The stock has a market cap of $7,990.00, a P/E ratio of -63.83 and a beta of 2.37.
In other news, insider Clay B. Siegall sold 18,832 shares of Seattle Genetics stock in a transaction dated Wednesday, October 11th. The stock was sold at an average price of $61.18, for a total value of $1,152,141.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Eric Dobmeier sold 3,729 shares of Seattle Genetics stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $58.75, for a total value of $219,078.75. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 157,210 shares of company stock worth $9,273,250. Company insiders own 34.70% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of SGEN. Quantbot Technologies LP raised its position in shares of Seattle Genetics by 116.5% in the 3rd quarter. Quantbot Technologies LP now owns 2,654 shares of the biotechnology company’s stock worth $144,000 after purchasing an additional 1,428 shares during the last quarter. Bristlecone Advisors LLC purchased a new position in shares of Seattle Genetics in the 3rd quarter worth about $180,000. Virtu Financial LLC purchased a new position in shares of Seattle Genetics in the 3rd quarter worth about $203,000. DRW Securities LLC purchased a new position in shares of Seattle Genetics in the 2nd quarter worth about $207,000. Finally, Caisse DE Depot ET Placement DU Quebec purchased a new position in shares of Seattle Genetics in the 3rd quarter worth about $208,000. 98.89% of the stock is owned by hedge funds and other institutional investors.
About Seattle Genetics
Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).
Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.